13Dec 2022
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

The present investigation describes the baseline characteristics of the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the largest cardiovascular (CV) outcome studies in the field of obesity, which evaluates the effect of semaglutide versus placebo on major CV events. The study enrolled 17,605 participants (72.5% male) with an average (SD) age of 61.6 (8.9) years and a BMI of 33.34 (5.04) kg/m2. Across groups of increasing HbA1c, the prevalence of all CV risk factors increased. The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups.

  • #endo-diabetology

Like

Save

Share